What you need to know about the historic FDA approval of a CRISPR-based drug for sickle cell

The drug approval is scientific triumph, and one that will usher in a new era of genetic medicines for inherited diseases.

December 8, 2023 Check out STAT+

Sponsored By

Christine Kao/STAT In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease The groundbreaking treatment, for sickle cell disease, is called Casgevy and was developed by Vertex and CRISPR Therapeutics. By Adam Feuerstein STAT+ | Sen. Warren pushes for more data on Medicare Advantage coverage hurdles, denials Senators are pushing the Biden administration to collect more data on Medicare Advantage coverage hurdles and claim denials. By Tara Bannow STAT+ | A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead The chief executive of CRISPR Therapeutics sits down for a conversation about a historic approval and the road ahead. By Adam Feuerstein Courtesy The Hills Tandem Opinion: After living with sickle cell disease for 39 years, I'm both excited and skeptical about the newly approved gene therapies Black Americans with sickle cell disease won't embrace gene therapy if companies don't address long-standing medical mistrust. By Jennifer Fields STAT+ | New proposals for scientific misconduct investigations worry some research universities The U.S. Office of Research Integrity wants a 30-day deadline for assessing allegations and safeguards against perfunctory dismissals for "honest errors." By Annalisa Merelli STAT+ | Medicare's advisory committee isn't sold on big pay raises for doctors On Thursday, the Medicare Payment Advisory Commission concluded that doctors shouldn't get more than a minor raise for 2025. By Brittany Trang Adobe Opinion: Clients bring politics into the therapy room. Here's what that means for the therapist Patients (and their therapists) arrive at any therapeutic moment at the nexus of social and political currents. By Sarah Darghouth

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser